GT Biopharma
GTBP
29 hedge funds and large institutions have $4.36M invested in GT Biopharma in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 10 reducing their positions, and 12 closing their positions.
2.21% less ownership
Funds ownership: 10.19% → 7.98% (-2.2%)
26% less funds holding
Funds holding: 39 → 29 (-10)
50% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 10
83% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 12
87% less capital inflows, than outflows
Capital inflows: $264K | Capital outflows: $2.04M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$84.1K |
| 2 |
Virtu Financial
New York
|
+$63.1K |
| 3 |
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
|
+$51.6K |
| 4 |
Goldman Sachs
New York
|
+$36.3K |
| 5 |
State Street
Boston,
Massachusetts
|
+$22.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$333K |
| 2 |
E
Ergoteles
New York
|
-$242K |
| 3 |
Millennium Management
New York
|
-$231K |
| 4 |
Renaissance Technologies
New York
|
-$193K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$182K |
GTBP Hedge Fund Activity: Q3 2022 in Review
29 of the 5,834 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q3 2022, worth a combined $4.36M — down 53% from $9.28M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of GTBP and 2 opened new positions — a net loss of 10 holders — while 10 trimmed existing stakes and 5 added.
The largest buyer was Jane Street, opening a new position worth an estimated $84.1K. The largest seller was Morgan Stanley, cutting an estimated $333K.
- 29 institutional investors held GT Biopharma (GTBP) as of Q3 2022, down from 39 in Q2 2022.
- Funds reported $4.36M of GT Biopharma stock for Q3 2022, down 53% quarter-over-quarter.
- 2 funds opened new GT Biopharma positions in Q3 2022 and 12 closed out, a net change of -10 holders.
- The largest GT Biopharma buyer in Q3 2022 was Jane Street, an estimated $84.1K added.
- The largest GT Biopharma seller in Q3 2022 was Morgan Stanley, an estimated $333K sold.
Based on aggregated 13F filings for Q3 2022.